--- title: "Anaptysbio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 25.56 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286153285.md" datetime: "2026-05-12T20:31:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286153285.md) - [en](https://longbridge.com/en/news/286153285.md) - [zh-HK](https://longbridge.com/zh-HK/news/286153285.md) --- # Anaptysbio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 25.56 M Revenue: As of FY2026 Q1, the actual value is USD 25.56 M, beating the estimate of USD 18.87 M. EPS: As of FY2026 Q1, the actual value is USD -1.84, missing the estimate of USD -0.7988. EBIT: As of FY2026 Q1, the actual value is USD -16.43 M. #### Operational Metrics AnaptysBio, Inc. reported an EBIT margin greater than 95% after completing the spin-off of First Tracks Biotherapeutics, Inc. in late April 2026 . The company announced a $100.0 million Stock Repurchase Plan in March 2026, which is set to expire on December 31, 2026 . #### Cash and Investments Cash, cash equivalents, and investments totaled $286.5 million as of March 31, 2026, representing a decrease of $25.1 million from $311.6 million as of December 31, 2025, primarily due to operating activities, partially offset by $14.0 million from stock option exercises . Total assets were $329.684 million as of March 31, 2026, down from $364.395 million as of December 31, 2025 . Total current assets decreased to $316.109 million from $350.250 million over the same period . #### Collaboration Revenue Collaboration revenue for the three months ended March 31, 2026, was $25.6 million, a decrease from $27.8 million for the same period in 2025 . This decline was mainly due to $9.7 million in revenue recognized from the Vanda license agreement in Q1 2025, which was partially offset by Jemperli royalties increasing 44% from $17.2 million to $24.7 million in Q1 2026 . #### Operating Expenses Research and development expenses for the three months ended March 31, 2026, decreased to $34.0 million from $41.2 million in the prior year period, primarily due to reduced development costs for rosnilimab and ANB032, offset by increased costs for ANB033 Phase 1 trials . General and administrative expenses increased to $26.2 million for the three months ended March 31, 2026, from $14.1 million in the prior year, mainly due to legal costs for company separation, ongoing GSK litigation, and non-cash stock compensation . Total operating expenses were $60.193 million for Q1 2026, compared to $55.310 million for Q1 2025 . #### Net Loss and Other Financials Net loss for the three months ended March 31, 2026, was -$52.9 million, compared to a net loss of -$39.3 million for the same period in 2025 . Loss from operations was -$34.637 million for Q1 2026, compared to -$27.539 million for Q1 2025 . Interest income was $2.653 million for Q1 2026, down from $4.413 million for Q1 2025 . Non-cash interest expense for the sale of future royalties was -$20.859 million for Q1 2026, compared to -$18.061 million for Q1 2025 . Total current liabilities increased to $41.702 million from $38.625 million, while the liability related to the sale of future royalties decreased to $263.742 million from $276.528 million as of March 31, 2026, and December 31, 2025, respectively . #### Outlook and Guidance AnaptysBio, Inc. anticipates achieving over $390 million in annualized Jemperli royalties as early as 2029, based on GSK’s peak sales guidance of over $2.7 billion . The company estimates that Sagard will have accrued approximately $275 million in royalties and sales milestones through Q1 2026 and expects the remaining approximately $325 million non-recourse debt monetization to be paid down by the end of Q2 2027 . For imsidolimab, the FDA target action date (PDUFA) is December 12, 2026, for its use in generalized pustular psoriasis (GPP) . ### Related Stocks - [ANAB.US](https://longbridge.com/en/quote/ANAB.US.md) ## Related News & Research - [AnaptysBio-Tesaro trial heads to post-trial briefs, argument set for Oct. 20](https://longbridge.com/en/news/294412038.md) - [Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained](https://longbridge.com/en/news/293377797.md) - [American Resources files amended 8-K detailing auditor change timeline after GreenGrowth withdraws 2025 opinion](https://longbridge.com/en/news/294229412.md) - [Ingredion amends 8-K to name Kenneth Escoe to audit committee](https://longbridge.com/en/news/294254664.md) - [Children’s Place amends 8-K to disclose Kim Roy separation deal, including $525,000 payment](https://longbridge.com/en/news/294257573.md)